Business Wire
19 Aug 2026, 10:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial for an mRNA-based individualized neoantigen therapy (INT) combined with KEYTRUDA. — Positive Phase 3 results for a novel cancer therapy significantly increase the probability of FDA approval and future commercial revenue for both companies.
+0.80Which stocks this story touches
The company announced positive topline results from a Phase 3 trial for a joint cancer therapy.
The company announced positive topline results from a Phase 3 trial for a joint cancer therapy.
Continue reading
6 related stories
Top 2 movers · tap to explore
[mutual] Merck and Moderna are jointly developing an mRNA-based individualized neoantigen therapy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
5h ago
